Selective cyclooxygenase-1 (COX-1) inhibitor (IC50
values are 0.028 and 65 μ
M for COX-1 and COX-2 respectively). Antiplatelet, analgesic and anti-inflammatory following oral administration in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The anti-platelet actions of FR122047, a novel cyclooxygenase inhibitor.
Dohi et al.
The analgesic effect profile of FR122047, a selective cyclo-oxygenase-1 inhibitor, in chemical nociceptive models.
Ochi et al.
Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis.
Ochi and Goto
Antiplatelet agents based on cyclooxygenase inhibition without ulcerogenesis. Evaluation and synthesis of 4,5-bis(4-methoxyphenyl)-2-substituted-thiazoles.
Tanaka et al.
The citations listed below are publications that use Tocris products. Selected citations for FR 122047 hydrochloride include:
Showing Results 1 - 6 of 6